All News
In Memoriam: Dr. K. Frank Austen (1928-2023)
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
Links:
Dr. John Cush RheumNow ( View Tweet)
Remembering Dr. Naomi F. Rothfield - As one of UConn School of Medicine’s first women faculty, legendary internationally-renowned rheumatologist Dr. had a nearly 50 year career at UConn Health retiring in 2016. She passed away on Sunday, July 2. https://t.co/jUESbCySRR https://t.co/50inpx7xRW
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew : Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK https://t.co/RuPZ0ys0xW
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @Yuz6Yusof : #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favored DAZ Group. Phase 3 RCTs are underway
Dr. John Cush RheumNow ( View Tweet)
RT @synovialjoints : • Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH)
• Bone pain, xanthelasma, hairy kidney
• Differential diagnoses of LCH
• BRAF mutation associated with cardiac and neurological phenotype of ECD
Haroche J, Papo M
Dr. John Cush RheumNow ( View Tweet)
RT @Janetbirdope : I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324. Small differences but maybe a script to go south is the right Rx!
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s new Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available.
https://t.co/38foNET3j4 https://t.co/8CjXwzyGab
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of FDA review times for New Indication Approvals of Drugs and Biologics (2017 - 2019) finds FDA approved 107 drugs for 146 new indications [99 small molecules (68%) & 47 biologics (32%)]. Median regulatory review time was 6 mos (IQR, 6-10) https://t.co/3P6T4R4FCF https://t.co/avl65W3kvr
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis
A large, retrospective, multinational study of patients with ANCA-AAV shows they may be at risk for CVEs.
https://t.co/k9XPolEXKc https://t.co/0nxai3Eqe2
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Delays Bimekizumab Decision, Again
UCB, the maker of the IL-17 A/F inhibitor bimekizumab (BMK), has announced that the FDA decision on BMK use in adults with moderate to severe plaque psoriasis has been delayed until the 3rd quarter of 2023.
https://t.co/u3wZp2xain https://t.co/pEldK1grb9
Links:
Dr. John Cush RheumNow ( View Tweet)
Taiwan claims data analysis of 1,830 scleroderma (SSc) pts & 27,981 controls showed increased incidence of SSc hospitalized w/ heart failure of 3.5%, 5.3%, & 9.7% (at 3, 5, 10 yrs). SSc patients had an increased risk of HF (adjusted HR 3.26) https://t.co/4WcHfiTJVF https://t.co/rW3J5aQdlS
Links:
Dr. John Cush RheumNow ( View Tweet)
Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/I6A8F4Kx7a https://t.co/njyciZFn52
Links:
Dr. John Cush RheumNow ( View Tweet)
Why Patients Don't Take Medicines
This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost.
https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Colchicine for CV Prevention
The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.
https://t.co/MEqASrWWMb https://t.co/TmoLEvlPXI
Links:
Dr. John Cush RheumNow ( View Tweet)
An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately given METFORMIN or Placebo. Cumulative incidence of long COVID at day 300 was 6.3% w/ metformin vs 10.4% w/ placebo (HR 0.59; HR 037 if given w/in 3d) https://t.co/aCTX7xFewW https://t.co/xbBeED9K7U
Links:
Dr. John Cush RheumNow ( View Tweet)
Uncertainty can be worrisome. When uncertainty lies ahead, optimism and preparation are your best navigators. Im an optimist. https://t.co/JNzWJFMEfV https://t.co/ltIdy6hNqn
Links:
Dr. John Cush RheumNow ( View Tweet)
Small study 57 EGPA pts shows using MTX or AZA to be equipotent as 1st or 2nd line therapy in EGPA. MTX pts used more cumulative steroids (6 g vs 10.7 g @5 yrs) & more AE (66% vs 30%); AZA had fewer asthma/ENT relapses (23% vs 64%, p= 0.04) https://t.co/WZHudojrzk https://t.co/X6xITcQtCw
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available.
https://t.co/0dV23VPDQH https://t.co/HfKhji40vU
Links:
Dr. John Cush RheumNow ( View Tweet)
Pediatric Rheumatologist Loan assistance repayment program from HSRA. A loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a 3-year, full-time service commitment at an approved facility in an underserved area https://t.co/6oFkEEKAY9
Links:
Dr. John Cush RheumNow ( View Tweet)
Using Optum claims data from 2009 to 2021, they identified 524 IgG4-RD pts (mean age 56 yrs), incidence increased over time 0.78 to 1.39/100K Pt Yrs 2015 and 2019. Prevalence (1/19) was 5.3/100K Pt-Yrs, w/ mortality rate 3.42/100 Pt-Yrs (HR 2.51) https://t.co/22eIjtC7kp https://t.co/8RlEtZiX9j
Links:
Dr. John Cush RheumNow ( View Tweet)
